BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
137 results:

  • 1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
    Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
    Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Concurrent KRAS p.G12C mutation and ANK3::ret fusion in a patient with metastatic colorectal cancer: a case report.
    Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
    Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes.
    Bull CJ; Hazelwood E; Legge DN; Corbin LJ; Richardson TG; Lee M; Yarmolinsky J; Smith-Byrne K; Hughes DA; Johansson M; Peters U; Berndt SI; Brenner H; Burnett-Hartman A; Cheng I; Kweon SS; Le Marchand L; Li L; Newcomb PA; Pearlman R; McConnachie A; Welsh P; Taylor R; Lean MEJ; Sattar N; Murphy N; Gunter MJ; Timpson NJ; Vincent EE
    EBioMedicine; 2024 Feb; 100():104977. PubMed ID: 38290287
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Impact of tissue-agnostic approvals on management of primary brain tumors.
    Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
    Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
    Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
    Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Pathologic Evaluation of Therapeutic Biomarkers in colorectal Adenocarcinoma.
    Baranov E; Nowak JA
    Surg Pathol Clin; 2023 Dec; 16(4):635-650. PubMed ID: 37863556
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Cost-Efficient Detection of
    Romanko AA; Mulkidjan RS; Tiurin VI; Saitova ES; Preobrazhenskaya EV; Krivosheyeva EA; Mitiushkina NV; Shestakova AD; Belogubova EV; Ivantsov AO; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762506
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors.
    Normanno N; Machado JC; Pescarmona E; Buglioni S; Navarro L; Esposito Abate R; Ferro A; Mensink R; Lambiase M; Lespinet-Fabre V; Calgua B; Jermann PM; Ilié M; Hofman P
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762091
    [TBL] [Abstract] [Full Text] [Related]  

  • 10.
    Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Incidence of medullary thyroid carcinoma and Hirschsprung disease based on the cosmos database.
    Wehrli LA; Reppucci ML; Ketzer J; Dominguez-Muñoz A; Cooper EH; Peña A; Bischoff A; De La Torre L
    Pediatr Surg Int; 2023 Jul; 39(1):227. PubMed ID: 37418029
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in ret-Aberrant Digestive Tract Tumours.
    Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
    Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. FDA Approval Summary: Selpercatinib for the Treatment of Advanced ret Fusion-Positive Solid Tumors.
    Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
    Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases.
    Fassi E; Mandruzzato M; Zamparini M; Bianchi S; Petrelli F; Baggi A; Alberti A; Grisanti S; Berruti A
    Lung Cancer; 2023 May; 179():107176. PubMed ID: 37015149
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Personalized Systemic Therapies in Hereditary cancer Syndromes.
    Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent.
    Qi B; Wang F; He H; Fan M; Hu L; Xiong L; Gong G; Shi S; Song X
    Eur J Med Chem; 2022 Sep; 239():114561. PubMed ID: 35763868
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Application of histology-agnostic treatments in metastatic colorectal cancer.
    Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
    Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable colorectal cancer.
    Madison RW; Hu X; Ramanan V; Xu Z; Huang RSP; Sokol ES; Frampton GM; Schrock AB; Ali SM; Ganesan S; De S
    JCO Precis Oncol; 2022 May; 6():e2100477. PubMed ID: 35584350
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support cancer Care.
    Sheffield BS; Beharry A; Diep J; Perdrizet K; Iafolla MAJ; Raskin W; Dudani S; Brett MA; Starova B; Olsen B; Cheema PK
    Curr Oncol; 2022 Feb; 29(3):1326-1334. PubMed ID: 35323313
    [No Abstract]    [Full Text] [Related]  


    [Next]

    of 7.